1
|
Bihanic C, Lasbleiz A, Regnier M, Petit E, Le Blainvaux P, Grison C. New Sustainable Synthetic Routes to Cyclic Oxyterpenes Using the Ecocatalyst Toolbox. Molecules 2021; 26:7194. [PMID: 34885776 PMCID: PMC8658900 DOI: 10.3390/molecules26237194] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2021] [Revised: 11/24/2021] [Accepted: 11/25/2021] [Indexed: 11/16/2022] Open
Abstract
Cyclic oxyterpenes are natural products that are mostly used as fragrances, flavours and drugs by the cosmetic, food and pharmaceutical industries. However, only a few cyclic oxyterpenes are accessible via chemical syntheses, which are far from being ecofriendly. We report here the synthesis of six cyclic oxyterpenes derived from ß-pinene while respecting the principles of green and sustainable chemistry. Only natural or biosourced catalysts were used in mild conditions that were optimised for each synthesis. A new generation of ecocatalysts, derived from Mn-rich water lettuce, was prepared via green processes, characterised by MP-AES, XRPD and TEM analyses, and tested in catalysis. The epoxidation of ß-pinene led to the platform molecule, ß-pinene oxide, with a good yield, illustrating the efficacy of the new generation of ecocatalysts. The opening ß-pinene oxide was investigated in green conditions and led to new and regioselective syntheses of myrtenol, 7-hydroxy-α-terpineol and perillyl alcohol. Successive oxidations of perillyl alcohol could be performed using no hazardous oxidant and were controlled using the new generation of ecocatalysts generating perillaldehyde and cuminaldehyde.
Collapse
Affiliation(s)
- Camille Bihanic
- Laboratory of Bio-inspirated Chemistry and Ecological Innovations (ChimEco), UMR 5021, CNRS—University of Montpellier Cap Delta, 1682 rue de la Valsière, 34790 Grabels, France; (C.B.); (A.L.); (M.R.)
| | - Arthur Lasbleiz
- Laboratory of Bio-inspirated Chemistry and Ecological Innovations (ChimEco), UMR 5021, CNRS—University of Montpellier Cap Delta, 1682 rue de la Valsière, 34790 Grabels, France; (C.B.); (A.L.); (M.R.)
| | - Morgan Regnier
- Laboratory of Bio-inspirated Chemistry and Ecological Innovations (ChimEco), UMR 5021, CNRS—University of Montpellier Cap Delta, 1682 rue de la Valsière, 34790 Grabels, France; (C.B.); (A.L.); (M.R.)
| | - Eddy Petit
- European Institute of Membrane (IEM), UMR 5635—University of Montpellier 163 rue Auguste Broussonet, 34090 Montpellier, France;
| | | | - Claude Grison
- Laboratory of Bio-inspirated Chemistry and Ecological Innovations (ChimEco), UMR 5021, CNRS—University of Montpellier Cap Delta, 1682 rue de la Valsière, 34790 Grabels, France; (C.B.); (A.L.); (M.R.)
- BioInspir Cap Delta, 1682 rue de la Valsière, 34790 Grabels, France;
| |
Collapse
|
2
|
Johansson NG, Dreano L, Vidilaseris K, Khattab A, Liu J, Lasbleiz A, Ribeiro O, Kiriazis A, Boije af Gennäs G, Meri S, Goldman A, Yli‐Kauhaluoma J, Xhaard H. Exploration of Pyrazolo[1,5-a]pyrimidines as Membrane-Bound Pyrophosphatase Inhibitors. ChemMedChem 2021; 16:3360-3367. [PMID: 34459148 PMCID: PMC8597055 DOI: 10.1002/cmdc.202100392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 08/03/2021] [Indexed: 11/08/2022]
Abstract
Inhibition of membrane-bound pyrophosphatase (mPPase) with small molecules offer a new approach in the fight against pathogenic protozoan parasites. mPPases are absent in humans, but essential for many protists as they couple pyrophosphate hydrolysis to the active transport of protons or sodium ions across acidocalcisomal membranes. So far, only few nonphosphorus inhibitors have been reported. Here, we explore the chemical space around previous hits using a combination of screening and synthetic medicinal chemistry, identifying compounds with low micromolar inhibitory activities in the Thermotoga maritima mPPase test system. We furthermore provide early structure-activity relationships around a new scaffold having a pyrazolo[1,5-a]pyrimidine core. The most promising pyrazolo[1,5-a]pyrimidine congener was further investigated and found to inhibit Plasmodium falciparum mPPase in membranes as well as the growth of P. falciparum in an ex vivo survival assay.
Collapse
Affiliation(s)
- Niklas G. Johansson
- Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of PharmacyUniversity of HelsinkiP.O. Box 56 (Viikinkaari 5 E)00014HelsinkiFinland
| | - Loïc Dreano
- Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of PharmacyUniversity of HelsinkiP.O. Box 56 (Viikinkaari 5 E)00014HelsinkiFinland
| | - Keni Vidilaseris
- Department of Biosciences, Division of BiochemistryUniversity of HelsinkiP.O. Box 56 (Viikinkaari 9)00014HelsinkiFinland
| | - Ayman Khattab
- Malaria Research Laboratory, Translational Immunology Research Program, Department of Bacteriology and Immunology, Haartman InstituteUniversity of HelsinkiP.O. Box 21 (Haartmaninkatu 3)00014HelsinkiFinland
| | - Jianing Liu
- Department of Biosciences, Division of BiochemistryUniversity of HelsinkiP.O. Box 56 (Viikinkaari 9)00014HelsinkiFinland
| | - Arthur Lasbleiz
- Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of PharmacyUniversity of HelsinkiP.O. Box 56 (Viikinkaari 5 E)00014HelsinkiFinland
| | - Orquidea Ribeiro
- Department of Biosciences, Division of BiochemistryUniversity of HelsinkiP.O. Box 56 (Viikinkaari 9)00014HelsinkiFinland
| | - Alexandros Kiriazis
- Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of PharmacyUniversity of HelsinkiP.O. Box 56 (Viikinkaari 5 E)00014HelsinkiFinland
| | - Gustav Boije af Gennäs
- Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of PharmacyUniversity of HelsinkiP.O. Box 56 (Viikinkaari 5 E)00014HelsinkiFinland
| | - Seppo Meri
- Malaria Research Laboratory, Translational Immunology Research Program, Department of Bacteriology and Immunology, Haartman InstituteUniversity of HelsinkiP.O. Box 21 (Haartmaninkatu 3)00014HelsinkiFinland
| | - Adrian Goldman
- Department of Biosciences, Division of BiochemistryUniversity of HelsinkiP.O. Box 56 (Viikinkaari 9)00014HelsinkiFinland
- School of Biomedical Sciences and Astbury Centre for Structural Molecular BiologyUniversity of Leeds, Clarendon WayLeeds LS2 9JTUK
| | - Jari Yli‐Kauhaluoma
- Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of PharmacyUniversity of HelsinkiP.O. Box 56 (Viikinkaari 5 E)00014HelsinkiFinland
| | - Henri Xhaard
- Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of PharmacyUniversity of HelsinkiP.O. Box 56 (Viikinkaari 5 E)00014HelsinkiFinland
| |
Collapse
|
3
|
Gaborit B, Ancel P, Abdullah AE, Maurice F, Abdesselam I, Calen A, Soghomonian A, Houssays M, Varlet I, Eisinger M, Lasbleiz A, Peiretti F, Bornet CE, Lefur Y, Pini L, Rapacchi S, Bernard M, Resseguier N, Darmon P, Kober F, Dutour A. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovasc Diabetol 2021; 20:57. [PMID: 33648515 PMCID: PMC7919089 DOI: 10.1186/s12933-021-01237-2] [Citation(s) in RCA: 54] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Accepted: 02/01/2021] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that has demonstrated cardiovascular and renal protection in patients with type 2 diabetes (T2D). We hypothesized that empaglifozin (EMPA) could modulate ectopic fat stores and myocardial energetics in high-fat-high-sucrose (HFHS) diet mice and in type 2 diabetics (T2D). METHODS C57BL/6 HFHS mice (n = 24) and T2D subjects (n = 56) were randomly assigned to 12 weeks of treatment with EMPA (30 mg/kg in mice, 10 mg/day in humans) or with placebo. A 4.7 T or 3 T MRI with 1H-MRS evaluation-myocardial fat (primary endpoint) and liver fat content (LFC)-were performed at baseline and at 12 weeks. In humans, standard cardiac MRI was coupled with myocardial energetics (PCr/ATP) measured with 31P-MRS. Subcutaneous (SAT) abdominal, visceral (VAT), epicardial and pancreatic fat were also evaluated. The primary efficacy endpoint was the change in epicardial fat volume between EMPA and placebo from baseline to 12 weeks. Secondary endpoints were the differences in PCr/ATP ratio, myocardial, liver and pancreatic fat content, SAT and VAT between groups at 12 weeks. RESULTS In mice fed HFHS, EMPA significantly improved glucose tolerance and increased blood ketone bodies (KB) and β-hydroxybutyrate levels (p < 0.05) compared to placebo. Mice fed HFHS had increased myocardial and liver fat content compared to standard diet mice. EMPA significantly attenuated liver fat content by 55%, (p < 0.001) but had no effect on myocardial fat. In the human study, all the 56 patients had normal LV function with mean LVEF = 63.4 ± 7.9%. Compared to placebo, T2D patients treated with EMPA significantly lost weight (- 2.6 kg [- 1.2; - 3.7]) and improved their HbA1c by 0.88 ± 0.74%. Hematocrit and EPO levels were significantly increased in the EMPA group compared to placebo (p < 0.0001, p = 0.041). EMPA significantly increased glycosuria and plasma KB levels compared to placebo (p < 0.0001, p = 0.012, respectively), and significantly reduced liver fat content (- 27 ± 23 vs. - 2 ± 24%, p = 0.0005) and visceral fat (- 7.8% [- 15.3; - 5.6] vs. - 0.1% [- 1.1;6.5], p = 0.043), but had no effect on myocardial or epicardial fat. At 12 weeks, no significant change was observed in the myocardial PCr/ATP (p = 0.57 between groups). CONCLUSIONS EMPA effectively reduced liver fat in mice and humans without changing epicardial, myocardial fat or myocardial energetics, rebutting the thrifty substrate hypothesis for cardiovascular protection of SGLT2 inhibitors. Trial registration NCT, NCT03118336. Registered 18 April 2017, https://clinicaltrials.gov/ct2/show/NCT03118336.
Collapse
Affiliation(s)
- B Gaborit
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France
- Department of Endocrinology, Metabolic Diseases and Nutrition, Pôle ENDO, APHM, Hôpital Nord, Chemin Des Bourrely, 13915, Marseille cedex 20, France
| | - P Ancel
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France
| | - A E Abdullah
- Department of Endocrinology, Metabolic Diseases and Nutrition, Pôle ENDO, APHM, Hôpital Nord, Chemin Des Bourrely, 13915, Marseille cedex 20, France
| | - F Maurice
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France
| | - I Abdesselam
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France
- Aix Marseille Univ, CNRS, CRMBM, Marseille, France
| | - A Calen
- Aix Marseille Univ, CNRS, CRMBM, Marseille, France
| | - A Soghomonian
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France
- Department of Endocrinology, Metabolic Diseases and Nutrition, Pôle ENDO, APHM, Hôpital Nord, Chemin Des Bourrely, 13915, Marseille cedex 20, France
| | - M Houssays
- Assistance-Publique Hôpitaux de Marseille, Medical Evaluation Department, CIC-CPCET, 13005, Marseille, France
| | - I Varlet
- Aix Marseille Univ, CNRS, CRMBM, Marseille, France
| | - M Eisinger
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France
- Department of Endocrinology, Metabolic Diseases and Nutrition, Pôle ENDO, APHM, Hôpital Nord, Chemin Des Bourrely, 13915, Marseille cedex 20, France
| | - A Lasbleiz
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France
- Aix Marseille Univ, CNRS, CRMBM, Marseille, France
| | - F Peiretti
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France
| | - C E Bornet
- Support Unit for Clinical Research and Economic Evaluation, Assistance Publique-Hôpitaux de Marseille, 13385, Marseille, France
| | - Y Lefur
- Aix Marseille Univ, CNRS, CRMBM, Marseille, France
| | - L Pini
- Aix Marseille Univ, CNRS, CRMBM, Marseille, France
| | - S Rapacchi
- Aix Marseille Univ, CNRS, CRMBM, Marseille, France
| | - M Bernard
- Aix Marseille Univ, CNRS, CRMBM, Marseille, France
| | - N Resseguier
- Support Unit for Clinical Research and Economic Evaluation, Assistance Publique-Hôpitaux de Marseille, 13385, Marseille, France
- Aix-Marseille Univ, EA 3279 CEReSS-Health Service Research and Quality of Life Center, Marseille, France
| | - P Darmon
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France
- Department of Endocrinology, Metabolic Diseases and Nutrition, Pôle ENDO, APHM, Hôpital Nord, Chemin Des Bourrely, 13915, Marseille cedex 20, France
| | - F Kober
- Aix Marseille Univ, CNRS, CRMBM, Marseille, France
| | - A Dutour
- Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France.
- Department of Endocrinology, Metabolic Diseases and Nutrition, Pôle ENDO, APHM, Hôpital Nord, Chemin Des Bourrely, 13915, Marseille cedex 20, France.
| |
Collapse
|